A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of Ranquilon, 1 mg tablets, at
a dose of 6 mg/day compared to placebo for the treatment of patients with anxiety in
neurasthenia and adjustment disorder.
An additional study objective was to evaluate the safety of Ranquilon, 1 mg tablets, at a
dose of 6 mg/day compared to placebo in patients with anxiety in neurasthenia and adjustment
disorder.